Search

Search Constraints

You searched for: Author/Creator Awad, Mark M.

Search Results

1. Abstracts Presented by Attendees. (February 2016)

2. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. (July 2019)

3. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib. Issue 2 (March 2020)

4. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. (October 2021)

5. Predictors of Rheumatic Immune‐Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Issue 3 (25th January 2022)

8. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. (25th August 2021)

9. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Issue 1 (3rd September 2021)

10. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. (2021)